Literature DB >> 20050391

Cost-effectiveness of routine rapid human immunodeficiency virus antibody testing before DNA-PCR testing for early diagnosis of infants in resource-limited settings.

Nicolas A Menzies1, Jaco Homsy, Jeannie Y Chang Pitter, Christian Pitter, Jonathan Mermin, Robert Downing, Thomas Finkbeiner, John Obonyo, Adeodata Kekitiinwa, Jordan Tappero, John M Blandford.   

Abstract

BACKGROUND: Infants born to HIV-infected women should receive HIV testing to allow early diagnosis and treatment. Recommendations for resource-limited settings stress laboratory-based virologic assays. While effective, these tests are logistically complex and expensive. This study explored the cost-effectiveness of incorporating initial screening with rapid HIV tests (RHT) into the conventional testing algorithm to screen-out HIV-uninfected infants, thereby reducing the need for costly virologic testing.
METHODS: Data on HIV prevalence, RHT sensitivity and specificity, and costs were collected from 820 HIV-exposed children (1.5-18 months) attending 2 postnatal screening programs in Uganda during July 2005 to December 2006. Cost-effectiveness models compared the conventional testing algorithm DNA polymerase chain reaction (DNA-PCR with Roche Amplicor v1.5) with a modified algorithm (initial RHT to screen-out HIV-uninfected infants before DNA-PCR).
RESULTS: The model estimated that the conventional algorithm would identify 94.3% (91.8%-94.7%) of HIV-infected infants, compared with 87.8% (79.4%-90.5%) for a modified algorithm using RHT (HIV 1/2 Determine) and excluding the need for DNA-PCR for HIV antibody-negative infants. Costs per infant were $23.47 ($23.32-$23.76) for the conventional algorithm and between $22.75 ($21.89-$23.31) and $7.58 ($6.41-$10.75) for the modified algorithm, depending on infant age and symptoms. Compared with the conventional algorithm, costs per HIV-infected infant identified using the modified algorithm were higher in 1.5-to 3-month-old infants, but significantly lower in 3-month-old and older infants. Models replicating the whole infant testing program showed the modified algorithm would have marginally lower sensitivity, but would reduce total program costs by 27% to 40%, producing an incremental cost-effectiveness ratio of $1489 ($686-$6781) for the conventional versus modified algorithms.
CONCLUSIONS: Screening infants with RHT before DNA-PCR is cost-effective in infants 3 months old or older. Incorporating RHT into early infant testing programs could improve cost-effectiveness and reduce program costs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20050391     DOI: 10.1097/inf.0b013e3181a3954b

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  Can Adolescents and Young Adults in Kenya Afford Free HIV Testing Services?

Authors:  Anjuli D Wagner; Kate S Wilson; Joseph B Babigumira; Cyrus Mugo; Peter M Mutiti; Jillian Neary; Dalton C Wamalwa; David Bukusi; Grace C John-Stewart; Pamela K Kohler; Jennifer A Slyker
Journal:  J Assoc Nurses AIDS Care       Date:  2020 Jul-Aug       Impact factor: 1.354

2.  Active tracking of rejected dried blood samples in a large program in Nigeria.

Authors:  Auchi Inalegwu; Sunny Phillips; Rawlings Datir; Christopher Chime; Petronilla Ozumba; Samuel Peters; Obinna Ogbanufe; Charles Mensah; Alash'Le Abimiku; Patrick Dakum; Nicaise Ndembi
Journal:  World J Virol       Date:  2016-05-12

3.  Infant/child rapid serology tests fail to reliably assess HIV exposure among sick hospitalized infants.

Authors:  Anjuli D Wagner; Irene N Njuguna; Ruth A Andere; Lisa M Cranmer; Helen M Okinyi; Sarah Benki-Nugent; Bhavna H Chohan; Elizabeth Maleche-Obimbo; Dalton C Wamalwa; Grace C John-Stewart
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

4.  Universal HIV screening at postnatal points of care: which public health approach for early infant diagnosis in Côte d'Ivoire?

Authors:  Camille Ndondoki; Hermann Brou; Marguerite Timite-Konan; Maxime Oga; Clarisse Amani-Bosse; Hervé Menan; Didier Ekouévi; Valériane Leroy
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 5.  Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions.

Authors:  Andrea L Ciaranello; Ji-Eun Park; Lynn Ramirez-Avila; Kenneth A Freedberg; Rochelle P Walensky; Valeriane Leroy
Journal:  BMC Med       Date:  2011-05-20       Impact factor: 8.775

Review 6.  Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review.

Authors:  Kira Elsbernd; Karl M F Emmert-Fees; Amanda Erbe; Veronica Ottobrino; Arne Kroidl; Till Bärnighausen; Benjamin P Geisler; Stefan Kohler
Journal:  Infect Dis Poverty       Date:  2022-07-15       Impact factor: 10.485

7.  Validation and calibration of a computer simulation model of pediatric HIV infection.

Authors:  Andrea L Ciaranello; Bethany L Morris; Rochelle P Walensky; Milton C Weinstein; Samuel Ayaya; Kathleen Doherty; Valeriane Leroy; Taige Hou; Sophie Desmonde; Zhigang Lu; Farzad Noubary; Kunjal Patel; Lynn Ramirez-Avila; Elena Losina; George R Seage; Kenneth A Freedberg
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

8.  Do diagnosis delays impact receipt of test results? Evidence from the HIV early infant diagnosis program in Uganda.

Authors:  Melissa Latigo Mugambi; Sarang Deo; Adeodata Kekitiinwa; Charles Kiyaga; Mendel E Singer
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

9.  Promising antibody testing strategies for early infant HIV infection diagnosis in China.

Authors:  Xueli Su; Jun Yao; Yan Jiang; Jie Li; Jianfeng Han; Weidong Sun
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

10.  Dried Blood Spot Test for HIV Exposed Infants and Children and Their Anti-Retro Viral Treatment Status in Selected Hospitals in Ethiopia.

Authors:  Beyene Wondafrash; Desta Hiko
Journal:  Ethiop J Health Sci       Date:  2016-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.